CHMP recommends approval of Lonquex (Teva) for chemotherapy-induced Neutropenia
The Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of a marketing authorisation for Lonquex (lipegfilgrastim), from Teva, for injection intended for prophylaxis against chemotherapy-induced Neutropenia.
The benefits with Lonquex are its ability to reduce the severity of neutropenia and the incidence of febrile neutropenia following the administration of myelotoxic chemotherapy. The most common side effects are musculoskeletal pains, thrombocytopenia, hypokalaemia, headache, skin reactions and chest pain.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.